Shareholder Paloma Partners Management Company Increased Nektar Therapeutics (NKTR) Stake

Nektar Therapeutics (NASDAQ:NKTR) Corporate LogoBig Money Sentiment decreased to 1.13 in Q2 2018. It has change of 0.30, from 2018Q1’s 1.43. The ratio worsened due to NKTR positioning: 54 sold and 100 reduced. 82 funds bought stakes and 92 increased stakes. Investors holded 153.40 million in 2018Q1 but now own 157.21 million shares or 2.48% more. Moreover, South Dakota Inv Council has 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR) for 5,100 shs. Global X Management Co Limited Liability holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 6,462 shs. British Columbia Mgmt has 0.02% invested in Nektar Therapeutics (NASDAQ:NKTR) for 48,383 shs. California State Teachers Retirement Systems holds 249,715 shs. Primecap Mgmt Ca, California-based fund reported 20.90 million shs. Toronto Dominion State Bank invested in 0.01% or 103,553 shs. Paloma Prtn Mgmt Co holds 0.37% or 415,300 shs. Price T Rowe Assoc Inc Md accumulated 1.92 million shs or 0.01% of the stock. Quantres Asset Management Ltd has 50,000 shs for 1.41% of their capital. Netherlands-based Apg Asset Nv has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Sectoral Asset Mngmt invested in 0.4% or 73,614 shs. Envestnet Asset holds 0% or 987 shs. Dnb Asset Mngmt As owns 16,200 shs. Alexandria Ltd Limited Liability Company owns 0.73% invested in Nektar Therapeutics (NASDAQ:NKTR) for 99,957 shs. 1,829 were accumulated by Piedmont Inv Advisors Ltd Liability Co.

NKTR had 21 selling transactions and 1 insider buy since May 16, 2018. This’s net activity of $18.63 million. The insider WHITFIELD ROY A bought 5,000 shs worth $290,212. GREER R SCOTT had sold 10,000 shs worth $602,786 on Monday, June 4. ROBIN HOWARD W sold $1.07 million worth of stock. $286,445 worth of Nektar Therapeutics (NASDAQ:NKTR) shs were sold by Doberstein Stephen K. On Wednesday, May 16 $298,203 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Thomsen Jillian B.. On Thursday, September 20 Ajer Jeffrey Robert also sold $383,130 worth of Nektar Therapeutics (NASDAQ:NKTR).

Paloma Partners Management Company’s stake in Nektar Therapeutics (NKTR) is rose by 19397.65% based on its latest 2018Q2 regulatory filing with the SEC. By buying 413,170 shares Paloma Partners Management Company made the stock popped up with 17.51%. At the end of 2018Q2, the 415,300 shares of the major pharmaceuticals company held by the institutional investor were valued at $20.28M, up from 2,130 at the end of the previous reported quarter. $5.87B is the MC of Nektar Therapeutics. Ticker’s shares touched $34.02 during the last trading session after 3.65% change.Nektar Therapeutics is uptrending after having risen 187.03% since November 10, 2017. NKTR has 2.90M volume or 29.91% up from normal. The stock outperformed the S&P500 by 171.41%.

According to a filing Paloma Partners Management Company decreased its stake in Newmont Mining (NYSE:NEM) by 90,310 shares to 63,190 shares, valued at $2.38M in 2018Q2. The fund operates about $5.47B US Long portfolio. Paloma Partners Management Company has cut its stake in Eog Resources Inc (Call) (NYSE:EOG) and also reduced its holding in Eog Resources Inc (NYSE:EOG) by 101,120 shares in the quarter, for a total of 13,780 shares.

For more Nektar Therapeutics (NASDAQ:NKTR) news published briefly go to: Benzinga.com, Streetinsider.com, Globenewswire.com, Businesswire.com or Nasdaq.com. The titles are as follows: “The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz’ Voluntary Recall” published on November 09, 2018, “Nektar Therapeutics (NKTR) PT Lowered to $81 at Mizuho Securities” on November 08, 2018, “SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar …” with a publish date: November 06, 2018, “Kessler Topaz Meltzer & Check, LLP – Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar …” and the last “Nektar Therapeutics (NKTR) Q3 2018 Earnings Conference Call Transcript” with publication date: November 08, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

A total of 6 analysts rate Nektar Therapeutics (NASDAQ:NKTR) as follows: 5 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 83% are bullish. (NASDAQ:NKTR) has 7 ratings reports on 10 Nov 2018 according to StockzIntelligence. On Tuesday, June 5 the company was maintained by Canaccord Genuity. On Thursday, November 8 the rating was maintained by Jefferies with “Buy”. On Monday, June 11 the firm earned “Neutral” rating by H.C. Wainwright. On Monday, June 4 the stock has “Overweight” rating by JP Morgan. On Monday, June 4 the rating was maintained by Cowen & Co with “Buy”. On Friday, May 11 the stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given by Canaccord Genuity.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.